Researchers have been working on a way to prevent RSV since the 1960s, without success. But on August 3, 2023, the CDC approved a drug called nirsevimab (trade name Beyfortus): a long-acting monoclonal antibody that is 80 percent effective at preventing hospitalizations and 90 percent effective at preventing intensive care unit admissions. Nirsevimab is administered as a single, intramuscular injection and can be given at the same time as other vaccines.

A Breakthrough Product for Babies